YBioC4002

YBioC4002 is a biologic drug candidate being developed by Yerlika Biopharma for the treatment of rheumatological conditions. The drug is currently in the registration phase, with an NDA/BLA already submitted and an expected market approval in 2025. It is formulated as an injectable in a pre-filled syringe (PFS), a delivery format typically used for subcutaneous administration in chronic autoimmune diseases. Yerlika Biopharma is a Turkish pharmaceutical company specializing in the production of biosimilars and other biologics through technology transfer and local manufacturing. Although the specific molecular target of YBioC4002 has not been publicly disclosed, it is part of the company's advanced pipeline of biosimilar candidates intended for the rheumatology market.